Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vysis Inc.

Division of Abbott Laboratories Inc.
www.vysis.com

Latest From Vysis Inc.

Business & Technology Briefs (08/2007)

Brief summaries of recent product and company developments in the device industry, including the demise of GE's proposed $8 billion acquisition of Abbott Diagnosticss, the Cytyc/Hologic merger, and Alsius' SPAC merger.

What's Next for Abbott in IVD?

Abbott and GE Healthcare broke off their $8.13 billion deal for Abbott's diagnostics and point-of-care businesses. The difficulty of delivering something so heavily integrated into Abbott appears to have surprised both sides. It's unlikely Abbott will seek another buyer and it is poised to make new investments in diagnostics. GE is also likely to continue pursuing more targeted acquisitions in diagnostics including, like Abbott, in molecular testing.
Medical Device Leadership

Molecular Diagnostics--From Tools to Tests

Instrument makers have made big money off the genomics revolution. But as the research market slows, companies are looking for new business opportunities. One area ripe for development: the molecular diagnostics market.
BioPharmaceutical Medical Device

The New Diagnostics Companies

A small number of start-ups are developing novel specilalty-focused diagnostics that capture drug-like revenues and margins without taking drug-like development and regulatory risks. Questions about the business model abound, since most companies need multiple tests to reach profitability and a changing regulatory climate may force these companies to seek FDA approval for their tests, dramatically increasing development risk and cost.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • John L Bishop, Pres. & CEO
    John R Sluis, SVP, CFO
    J. L Fox, PhD, VP, Tech. & Bus. Dev.
    George R Kennedy, SVP, Sales & Mktg.
    Steven A Seelig, PhD, VP, R&D
  • Contact Info
  • Vysis Inc.
    Phone: (630) 271-7000
    3100 Woodcreek Dr.
    Downers Grove, IL 60515-5424
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register